New York: (Web Desk) Pfizer Inc. Chief Executive Officer Albert Bourla said he had tested positive for COVID-19.
“I’m feeling well and symptom-free,” Bourla said in a statement.
According to the source, Bourla, 60, back in August had contacted COVID and had started a course of the company’s oral COVID-19 antiviral treatment, Paxlovid. It (Paxlovid) is an antiviral medication that is used to treat high-risk people, such as older patients.
Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech.
Furthermore the chief executive said he has not yet taken the new bivalent booster.
Developed by Moderna and the team of Pfizer and BioNTech, the new so-called bivalent shots aim to tackle the BA.5 and BA.4 Omicron sub-variants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the United States, based on latest data.
Bourla is also added that “I have not had the new bivalent booster yet, as I was following CDC guidelines to wait three months since my previous COVID case which was back in mid-August.”
In August, the FDA authorized Pfizer and Moderna’s updated booster shots that target the dominant BA.4 and BA.5 Omicron sub-variants.
A federal health agency said this week that over 25 million doses of the so-called bivalent shots had been sent out. That consisted of mostly the Pfizer/BioNTech vaccine, as production of the Moderna vaccine ramps up.
